Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway.
about
Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signalingMacropinocytosis Exploitation by Cancers and Cancer TherapeuticsIntegrative analysis of kinase networks in TRAIL-induced apoptosis provides a source of potential targets for combination therapyMonocyte chemoattractant protein-1 induces a novel transcription factor that causes cardiac myocyte apoptosis and ventricular dysfunctionActivation of Ras up-regulates pro-apoptotic BNIP3 in nitric oxide-induced cell deathGlycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosisA randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance.Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterationsH-Ras regulation of TRAIL death receptor mediated apoptosisc-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cellsEGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells.F-box protein 10, an NF-κB-dependent anti-apoptotic protein, regulates TRAIL-induced apoptosis through modulating c-Fos/c-FLIP pathwayThe TRAIL of oncogenes to apoptosis.ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS.Targeted expression of tumor necrosis factor-related apoptosis-inducing ligand TRAIL in skin protects mice against chemical carcinogenesis.Death pathways triggered by activated Ras in cancer cellsDeep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS MutationsDelivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo.ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models: efficiency of DAT1 in Ras-Raf mutated cells.Multifaceted targeting in cancer: the recent cell death players meet the usual oncogene suspects.TRAIL induces apoptosis in oral squamous carcinoma cells--a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5.Ras and rheb signaling in survival and cell deathTargeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis.Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species.Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through ERK-dependent up-regulation of TRAIL receptor DR5.ERK and cell death: mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence.Sensitization of (colon) cancer cells to death receptor related therapies: a report from the FP6-ONCODEATH research consortium.Death receptors as targets in cancerAn RNA interference screen identifies new avenues for nephroprotection.Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis.Effects of Decitabine on the proliferation of K562 cells and the expression of DR4 gene.
P2860
Q24296451-F2BF99EF-BD79-428B-8AB4-DDBD6B4D3C3AQ28069487-4636D8FB-FC8B-409F-9D7D-F4CE34166140Q28115758-3BD4F10D-94FF-445E-B241-34EAF7FB34B1Q28116119-615E6F9F-198C-44C4-90B3-FCA04FB081E9Q28505436-1B614BB6-5B05-4163-B92F-C159D1ED329FQ28729017-8AD8AA82-D9E0-494F-AEC5-B1055EEA3932Q33401816-AF7B1B14-61B7-4DEE-8AD8-1E769BEEA388Q33955186-C11B05F8-AD32-4CAF-BCF4-3D79257728D5Q34068205-EDE1E13C-252C-4BFB-9B35-4989EB419EE7Q34104161-991BB422-34F9-44C6-BF48-7BA2468ED79FQ34139663-B11CF361-4B27-42EF-B2B0-CEF4A9F7A326Q34149887-95E035D1-EA6D-44E5-89B7-2565C300FF20Q34160097-F9854FEA-0C1D-4EA4-8D83-FB453224C36DQ34354511-CE007B1B-D9E5-4384-B6C1-FB7F033C6B4AQ34438717-47C19E5B-7E33-4026-AA30-5874CD4B3DAAQ34600157-D1529560-D2E5-442A-BE17-1E7DF040281EQ34809370-894FE46A-1BD0-4A99-9B19-A8954B6016E3Q34994888-607C6B12-5CA8-4986-9141-4538FB0FF5ECQ35971891-DF47D345-75A9-4A60-9392-96CE1477616DQ36395984-6DC26ABE-F888-4AC6-A1DF-424B77440B61Q36608654-EAE27268-2886-478C-B21D-230E4DB78E62Q36662230-BB36F11B-2C17-4EAA-AECC-00C73F417237Q36804432-A6F5D78C-1886-44C7-877A-1AB8D36187B3Q37016549-34B688B2-87FF-4A95-9810-3BB0EB91C68BQ37061781-78126467-9C9B-4F57-B443-27923BCEF5FAQ37246966-ABA5E7FE-1F9E-4C52-B9B1-551B299FD15BQ37341171-3305C5EA-9BA2-45C3-994C-53AD8BC1B296Q37462106-AFE91BB2-AE99-46E8-B9EB-5D624E20ECD2Q37618297-20147E63-DAA8-4223-B62A-C6CD0D9ADFB4Q37992502-4330DB7F-1640-48D9-9700-67B73087A4CAQ38103591-08A43DD6-A57A-43A8-9087-CECD8FB25406Q38819738-E562BCEB-271A-4707-B9C5-681070866737Q40038240-EA9C980D-61BE-4A22-BB07-8663E96A40DEQ42097322-4F08FEFA-3379-4EBA-9FF6-B0A1FBDFC941Q50190216-DC14C702-110E-4108-B9FA-15E67FBCE80A
P2860
Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Transformation by oncogenic RA ...... rough a MEK-dependent pathway.
@en
type
label
Transformation by oncogenic RA ...... rough a MEK-dependent pathway.
@en
prefLabel
Transformation by oncogenic RA ...... rough a MEK-dependent pathway.
@en
P2093
P2860
P356
P1476
Transformation by oncogenic RA ...... rough a MEK-dependent pathway.
@en
P2093
Alexander Pintzas
Konstantinos G Drosopoulos
Ladislav Andera
Lukas Cermak
Michael L Roberts
Senji Shirasawa
Takehiko Sasazuki
P2860
P304
22856-22867
P356
10.1074/JBC.M412483200
P407
P577
2005-03-08T00:00:00Z